M.C. Di Paolo

ORCID: 0000-0001-6891-4114
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Esophageal and GI Pathology
  • Colorectal Cancer Screening and Detection
  • Eosinophilic Esophagitis
  • Gastrointestinal disorders and treatments
  • Gastric Cancer Management and Outcomes
  • Gut microbiota and health
  • Diverticular Disease and Complications
  • Celiac Disease Research and Management
  • Pharmaceutical studies and practices
  • Helicobacter pylori-related gastroenterology studies
  • Diagnosis and treatment of tuberculosis
  • Probiotics and Fermented Foods
  • Gastrointestinal motility and disorders
  • Health Systems, Economic Evaluations, Quality of Life
  • Gastrointestinal Tumor Research and Treatment
  • Autoimmune and Inflammatory Disorders
  • Biosimilars and Bioanalytical Methods
  • Mycobacterium research and diagnosis
  • Systemic Lupus Erythematosus Research
  • Pressure Ulcer Prevention and Management
  • Complementary and Alternative Medicine Studies
  • COVID-19 and healthcare impacts

Azienda Ospedaliera San Giovanni Addolorata
2008-2025

Ospedale Regina Margherita
2008

National Hospital
2008

Sapienza University of Rome
1995-2001

Northwestern University
1991

University of Pavia
1990

Some evidence indicates that short-chain fatty acid (SCFA) enemas are effective in the treatment of distal ulcerative colitis.In a randomized, double-blind, placebo-controlled study, we tested efficacy 6-week course topical SCFA (100 mL, twice daily sodium acetate 80 mmol/L, propionate 30 mmol/L and butyrate 40 mmol/L) patients with mild to moderate colitis. Clinical, endoscopic histological data were collected at beginning end study.Fourteen on improved (overall score 11.3 +/- 2.0 vs. 7.4...

10.1111/j.1365-2036.1995.tb00386.x article EN Alimentary Pharmacology & Therapeutics 1995-06-01

To investigate in symptomatic uncomplicated diverticular disease the efficacy of symbiotics associated with a high-fibre diet on abdominal symptoms.This study was multicentre, 6-mo randomized, controlled, parallel-group intervention preceding 4-wk washout period. Consecutive outpatients disease, aged 40-80 years, evaluated 4 Gastroenterology Units, were enrolled. Symptomatic patients randomized to two treatment arms A or B. Treatment (n = 24 patients) received 1 symbiotic sachet Flortec(©)...

10.3748/wjg.v18.i41.5918 article EN cc-by-nc World Journal of Gastroenterology 2012-01-01

Probiotics are microorganisms that confer benefits to the host, and, for this reason, they have been proposed in several pathologic states. Specifically, probiotic bacteria investigated as a therapeutic option ulcerative colitis (UC) patients, but clinical results dishomogeneous. In particular, many species with different schemes proposed, no study has probiotics monotherapy adequate trials induction of remission. Lactobacillus rhamnosus GG (LGG) is more intensively studied and it ideal...

10.3390/microorganisms11061381 article EN cc-by Microorganisms 2023-05-24

AIM:To investigate in a prospective study whether simplified clinical score prior to endoscopy upper gastrointestinal bleeding (UGIB) patients was able predict endoscopic findings at urgent endoscopy.METHODS: All consecutive UGIB referred single center during 16 mo period were enrolled.Before stratified according simple (T-score), including T1 (high-risk), T2 (intermediate-risk) and T3 (low-risk).Endoscopy performed all cases within 2 h, high-risk stigmata considered for further...

10.3748/wjg.14.5046 article EN cc-by-nc World Journal of Gastroenterology 2008-01-01

Background and aim: Complementary alternative medicines (CAM) are being used increasingly by patients with Crohn's disease (CD) ulcerative colitis (UC). We aimed to assess the prevalence usage of CAM in different geographical areas Italy possible predictors their use.

10.1016/j.crohns.2009.12.009 article EN Journal of Crohn s and Colitis 2010-01-19

The role of endoscopic evaluation in ulcerative colitis (UC) is well recognized, but a universally accepted gold standard for activity still lacking, and many scores have been proposed to this purpose. Among these, the Mayo Endoscopic Score (MES) Ulcerative Colitis Index (UCEIS) are currently most used trials clinical practice. aim study evaluate feasibility performance MES UCEIS among expert endoscopists with no specific expertise inflammatory bowel diseases (IBD), single hospital center....

10.3390/gastroent12020019 article EN cc-by Gastroenterology Insights 2021-05-06

Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety Italian UC patients.A retrospective assessment clinical endoscopic activity was performed according Mayo score. The primary endpoints were evaluate effectiveness TOF.We enrolled 166 a median follow-up 24 (IQR 8-36) weeks. Clinical remission achieved 61/166 (36.7%) 75/166 (45.2%) at 8-week 24-week follow-ups, respectively....

10.1080/14656566.2023.2230126 article EN Expert Opinion on Pharmacotherapy 2023-06-26

Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn’s disease (CD). Only limited real-life data on long-term outcomes CD patients treated with UST are available. This study assessed UST’s effectiveness and safety in a large population-based cohort moderate to severe patients. Methods: was multicenter, retrospective, observational that included both naïve biologic-experienced who achieved clinical remission or response...

10.3390/jcm13237192 article EN Journal of Clinical Medicine 2024-11-27

Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Mayo score the Harvey-Bradshaw Index (HBI) scored clinical activity. Achievement maintenance of remission during follow-up, safety were primary endpoints.729 patients (475 254 CD), median follow-up 18 (IQR 6-36) months, enrolled. Clinical at 6th month treatment was achieved 488 (66.9%) (74.4% 62.9% UC, p<0.002) while, no...

10.1080/14712598.2023.2185510 article EN Expert Opinion on Biological Therapy 2023-02-27

In this pilot study, we assessed the role of autophagy in Crohn's Disease (CD), particularly patients with a stenosing phenotype. Through analysis biopsied specimens from 36 patients, including 11 controls and 25 CD categorized into inflammatory groups, identified significant reduction autophagosomal marker Lc3b-II active inflammation stenosis. This was paralleled by an increase oxidative stress markers, sNOX2-dp H2O2, decrease antioxidant capacity measured HBA, suggesting imbalance...

10.1038/s41598-024-79308-z article EN cc-by-nc-nd Scientific Reports 2024-11-09

A 14 month old girl was found to have a deletion of the whole band 5q23. By comparing 19 other cases monosomic for part 5q13-q31 segment, constitutional 5q interstitial deletions fall into two groups: adult patients with Gardner-like symptoms and mental retardation associated 5q21-q22, (mostly children) unspecific signs different deletions.

10.1136/jmg.27.4.267 article EN Journal of Medical Genetics 1990-04-01

Helicobacter pylori (Hp) infection can be diagnosed by invasive and noninvasive methods, and, among the former, Rapid Urease Tests (RUTs) are an important option. Accuracy rapidity of results fundamental for RUTs. The aim study is to prospectively evaluate sensitivity, specificity time positivity a new-generation ultra-rapid urease test (iNatal duo test) Hp detection compare with other available RUTs [CLO Test (Campylobacter-Like Organism Test), CP (Campylobacter Test) Pronto Dry]. Gastric...

10.3390/gidisord4030019 article EN cc-by Gastrointestinal Disorders 2022-08-26
Coming Soon ...